ZBIO (Zenas BioPharma) Current Accrued Expense : $30.85 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Current Accrued Expense?

Zenas BioPharma's Current Accrued Expense for the quarter that ended in Dec. 2024 was $30.85 Mil.

Zenas BioPharma's quarterly Current Accrued Expense declined from Jun. 2024 ($25.88 Mil) to Sep. 2024 ($22.34 Mil) but then increased from Sep. 2024 ($22.34 Mil) to Dec. 2024 ($30.85 Mil).

Zenas BioPharma's annual Current Accrued Expense declined from Dec. 2022 ($15.11 Mil) to Dec. 2023 ($11.88 Mil) but then increased from Dec. 2023 ($11.88 Mil) to Dec. 2024 ($30.85 Mil).

Zenas BioPharma Current Accrued Expense Historical Data

The historical data trend for Zenas BioPharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Current Accrued Expense Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Current Accrued Expense

15.11

11.88

30.85

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial				11.88	16.96	25.88	22.34	30.85

Zenas BioPharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Zenas BioPharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.